Administration of timolol to one eye is associated with a decrease in intraocular pressure in both eyes. To further investigate this effect the contralateral decrease in intraocular pressure was measured in a three arm crossover study using a 0 1 mg dose oftimolol given topically to an eye, a 0 1 mg dose oftimolol given lingually, and a placebo given topically. Two hours after topical timolol administration the mean intraocular pressure reduction in the fellow eye was 3*1 mm Hg compared with baseline (p=00007). Two hours after lingual timolol admi'nistration the mean intraocular pressure reduction was 3-9 mm Hg compared with baseline (p=00004 (Fig 1) . There was no difference between the pretreatment and post-treatment systolic or diastolic blood pressure. There was a significant reduction in pulse, from a mean pretreatment pulse of 74-9 to a mean post-treatment pulse of 67-3 (p=0 0045).
The contralateral reduction of intraocular pressure by timolol Cynthia N Dunham, Richard F Spaide, Gerald Dunham Abstract Administration of timolol to one eye is associated with a decrease in intraocular pressure in both eyes. To further investigate this effect the contralateral decrease in intraocular pressure was measured in a three arm crossover study using a 0 1 mg dose oftimolol given topically to an eye, a 0 1 mg dose oftimolol given lingually, and a placebo given topically. Two hours after topical timolol administration the mean intraocular pressure reduction in the fellow eye was 3*1 mm Hg compared with baseline (p=00007). Two hours after lingual timolol admi'nistration the mean intraocular pressure reduction was 3-9 mm Hg compared with baseline (p=00004). Two hours after topical administration of placebo the mean intraocular pressure reduction in the fellow eye was only 033 (Fig 1) . There was no difference between the pretreatment and post-treatment systolic or diastolic blood pressure. There was a significant reduction in pulse, from a mean pretreatment pulse of 74-9 to a mean post-treatment pulse of 67-3 (p=0 0045).
In the lingual application phase of the study the mean initial intraocular pressures in the two eyes were 13- Hours after timolol administration topical study was 3-1 mm Hg (p=00007, compared with mean initial pressure) at 1 hour and 3-6 mm Hg at 2 hours (p=0 0007). Likewise, the mean drop in intraocular pressure in the eye that was the fellow eye of the topical phase of the study was 3-2 mm Hg (p=00007, compared with mean initial pressure) at 1 hour and 3-9 mm Hg (p=0 0004) at 2 hours (Fig 2) . There was no difference between the pretreatment and posttreatment systolic or diastolic blood pressure in the lingual application phase of the study. There was a significant decrease in pulse in the lingual application phase from a mean pretreatment pulse of 70 9 to a mean post-treatment pulse of 66-6 (p=0 0086).
In the placebo phase of the study there was no change from baseline in the mean intraocular pressure ofthe treated eye. The mean intraocular pressure in the fellow eye in the placebo arm of the study decreased 0 33 mm Hg over 2 hours, an amount that did not reach statistical significance (p=0 6). The changes in systolic blood pressure, diastolic blood pressure, and pulse were not statistically significant.
The mean intraocular pressure drop of the treated eye in the topical application phase of the study was greater than the drop in intraocular pressure of the same eye in the lingual phase at 1 and 2 hours, but the difference did not reach statistical significance (p=0-8 and p=0-27 respectively). On the other hand, the mean intraocular pressure drop of the fellow eye in the topical application phase was less than the drop in intraocular pressure of the same eye in the lingual application phase of the study at 1 and 2 hours, but the difference did not reach statistical significance (p=0069 and p=0-23 respectively). The change in pulse rate in the topical group compared with the lingual group was not significantly different, but there was a significant difference in the change in pulse rate between the control and the topical and lingual groups (Fig 3) .
Discussion
As expected, topical application of timolol caused a reduction in intraocular pressure in the treated eye as well as the untreated fellow eye. At 2 hours the contralateral eye experienced a drop in intraocular pressure that was 704% of the drop in the treated eye, which was somewhat greater than the contralateral effect seen in past studies.'1' The reason for the greater contralateral effect is a matter of speculation, but all studies had both small sample sizes and probable differences in subject selection that might have preferentially biased the results obtained.
Lingual application of timolol also caused an intraocular pressure reduction. This reduction was less than that obtained from direct topical treatment, but was somewhat greater than the contralateral effect seen in the topical application phase of the study. The similar reduction in pulse noted by both routes of administration suggests that timolol may be systemically absorbed to the same degree by both routes. Past studies have demonstrated an intraocular pressure reduction from oral ingestion of j3 adrenergic blocking agents given in pill form.67 These studies differ from the present study in several ways. The doses administered in the past studies were orders of magnitude greater than the 0 1 mg dose given in this study.67 Past studies used pills which were swallowed. It has been shown that when , adrenergic blocking agents are swallowed they undergo a first pass effect in the liver and this reduces the amount of drug reaching end organs.8 The small volume given to the subjects in the present study was difficult to swallow, and may have resulted in direct absorption through the oral mucosa, thus bypassing the first pass effect in the liver. 9 Topical application of timolol to the eye 17 r results in systemic absorption, mainly through the conjunctiva and mucosa of the nasopharynx. In an animal model, application of timolol in one eye produced measurable levels of drug in the contralateral eye. 0 The ocular hypotensive effect of timolol is much less in animal than humans and was not measured in that study.'0 The results ofthe present study suggest that the contralateral reduction of intraocular pressure from timolol is due to systemic absorption. The magnitude of the contralateral intraocular pressure reduction in this and previous studies raises questions about the penetration and pharmacodynamics of timolol in the treated eye.
Although topical application of timolol readily elevates the aqueous humour concentration of the drug, experiments in animal models show that timolol readily binds to melanin pigment of the iris"I and is also eliminated from the iris by the blood circulation. The net fluid flow is from the ciliary body to the anterior chamber, resulting in aqueous flow dynamics that reduces access of timolol to the ciliary processes.'2 The combination of these factors leads to decreased penetration of timolol into the posterior chamber,'0 thus reducing passage of the drug directly to the ciliary body. It is possible that the intraocular pressure reduction seen in the treated eye is the result of the combined effects of the direct penetration into the eye as well as systemic absorption of the drug.
The main reason 13 blockers are given topically is to avoid systemic side effects. These side effects may limit the use of 13 
